Guided Therapeutics (GTHP) Net Margin (2010 - 2025)
Guided Therapeutics' (GTHP) quarterly Net Margin came in at 202.71% in Q4 2025, up 6979729.0% year-on-year from N/an in Q4 2024, and up 84.51% quarter-over-quarter from 1308.33% in Q3 2025.
Guided Therapeutics (GTHP) Net Margin (2010 - 2025) Analysis & Trends
Guided Therapeutics has disclosed Net Margin across 16 years of filings, most recently posting 202.71% for Q4 2025.
- Net Margin for Q4 2025 came in at 202.71%, up 6979729.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 430.25% (up 3658404.0% YoY), and the FY2025 annual result was 430.25%, up 3658404.0% from the prior year.
- Net Margin came in at 202.71% for Q4 2025 at Guided Therapeutics, up from 1308.33% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 202.71% in Q4 2025 to a low of 70000.0% in Q4 2024.
- The 5-year median for Net Margin is 4025.0% (2023), against an average of 16039.17%.
- Across the five-year window, Net Margin plunged 6853438 bps in 2024 and soared 6979729 bps in 2025, its largest moves.
- Guided Therapeutics' Net Margin stood at 848.33% in 2021, then plunged by 4041 bps to 35133.33% in 2022, then surged by 96 bps to 1465.62% in 2023, then sank by 4676 bps to 70000.0% in 2024, then surged by 100 bps to 202.71% in 2025.
- The last three Net Margin figures came in at 202.71% (Q4 2025), 1308.33% (Q3 2025), and 731.62% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.65% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.38% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 12.75% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 25.77% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.00% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 16.74% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 8.01% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | - |
| 10 | Guided Therapeutics | - | - | 458,000.00 | -202.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -202.71% |
| Sep 30, 2025 | -1,308.33% |
| Jun 30, 2025 | -731.62% |
| Dec 31, 2024 | -70,000.00% |
| Mar 31, 2024 | -7,350.00% |
| Dec 31, 2023 | -1,465.63% |
| Jun 30, 2023 | -3,645.45% |
| Mar 31, 2023 | -4,404.55% |
| Sep 30, 2022 | -35,133.33% |
| Jun 30, 2022 | -20,140.00% |
| Mar 31, 2022 | -21,100.00% |
| Dec 31, 2021 | -848.33% |
| Sep 30, 2021 | -268.42% |
| Jun 30, 2021 | -57,950.00% |
| Dec 31, 2020 | 8,476.00% |
| Sep 30, 2020 | 1,985.71% |
| Dec 31, 2019 | 6,768.75% |
| Sep 30, 2019 | -12,600.00% |
| Jun 30, 2019 | -265,400.00% |
| Mar 31, 2019 | -1,244.44% |